AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
HIGH-DOSE OF CPT-11 (500 MG M(2)) AS FIRST LINE CHEMOTHERAPY FOR METASTATIC COLORECTAL-CANCER - PRELIMINARY-RESULTS OF A MULTICENTER PHASE-II TRIAL/
Authors: YCHOU M KRAMAR A RAOUL JL DESSEIGNE F BOREL C JACOB H HUA A WEINLING E MERROUCHE Y
Citation: M. Ychou et al., HIGH-DOSE OF CPT-11 (500 MG M(2)) AS FIRST LINE CHEMOTHERAPY FOR METASTATIC COLORECTAL-CANCER - PRELIMINARY-RESULTS OF A MULTICENTER PHASE-II TRIAL/, Annals of oncology, 9, 1998, pp. 181-181
VINORELBINE AND CISPLATIN (CIVIC REGIMEN) FOR THE TREATMENT OF METASTATIC BREAST-CARCINOMA AFTER FAILURE OF ANTHRACYCLINE-CONTAINING AND ORPACLITAXEL-CONTAINING REGIMENS/
Authors: RAYCOQUARD I BIRON P BACHELOT T GUASTALLA JP CATIMEL G MERROUCHE Y DROZ JP CHAUVIN F BLAY JY
Citation: I. Raycoquard et al., VINORELBINE AND CISPLATIN (CIVIC REGIMEN) FOR THE TREATMENT OF METASTATIC BREAST-CARCINOMA AFTER FAILURE OF ANTHRACYCLINE-CONTAINING AND ORPACLITAXEL-CONTAINING REGIMENS/, Cancer, 82(1), 1998, pp. 134-140
STANDARDS, OPTIONS AND RECOMMENDATIONS FOR THE FOLLOW-UP AFTER TREATMENT FOR COLONIC-CANCER
Authors: CONROY T ADENIS A LASSER P MERROUCHE Y MONGES G RIVOIRE M ROUGIER P RUGGIERIPIGNON S SARRADET A TOMA C
Citation: T. Conroy et al., STANDARDS, OPTIONS AND RECOMMENDATIONS FOR THE FOLLOW-UP AFTER TREATMENT FOR COLONIC-CANCER, Bulletin du cancer, 85(2), 1998, pp. 152-159
CAN WE DEFINE THE MECHANISM OF ANTITUMOR RESPONSE OBSERVED DURING CLINICAL ADOPTIVE IMMUNOTHERAPY
Authors: MERROUCHE Y NEGRIER S PUISIEUX I FAVROT M
Citation: Y. Merrouche et al., CAN WE DEFINE THE MECHANISM OF ANTITUMOR RESPONSE OBSERVED DURING CLINICAL ADOPTIVE IMMUNOTHERAPY, Journal of the National Cancer Institute, 89(18), 1997, pp. 1380-1380
ADDITION OF OXALIPLATIN (ELOXATINE(R), LOHP) TO THE SAME LEUCOVORIN (LV) AND 5-FLUOROURACIL (5FU) BIMONTHLY REGIMENS AFTER PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL-CANCER (MCRC) - PRELIMINARY-REPORT
Authors: ANDRE T BENSMAINE MA LOUVET C LUCAS V BEERBLOCK K DESSEIGNE F FRANCOIS E MERROUCHE Y BOUCHE O MORVAN F CAROLA E DEGRAMONT A
Citation: T. Andre et al., ADDITION OF OXALIPLATIN (ELOXATINE(R), LOHP) TO THE SAME LEUCOVORIN (LV) AND 5-FLUOROURACIL (5FU) BIMONTHLY REGIMENS AFTER PROGRESSION IN PATIENTS (PTS) WITH METASTATIC COLORECTAL-CANCER (MCRC) - PRELIMINARY-REPORT, European journal of cancer, 33, 1997, pp. 738-738
ABSOLUTE BIOAVAILABILITY AND PHARMACOKINETICS (PK) OF ORAL VINORELBINE (VRL) IN PATIENTS (PTS) WITH SOLID TUMORS
Authors: PUOZZO C FUMOLEAU P ADENIS A ROUSSEAU F MERROUCHE Y ROBINET G SENAC I MARTY M
Citation: C. Puozzo et al., ABSOLUTE BIOAVAILABILITY AND PHARMACOKINETICS (PK) OF ORAL VINORELBINE (VRL) IN PATIENTS (PTS) WITH SOLID TUMORS, European journal of cancer, 33, 1997, pp. 1118-1118
HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY
Authors: MERROUCHE Y EXTRA JM ABIGERGES D BUGAT R CATIMEL G SUC E MARTY M HERAIT P MAHJOUBI M ARMAND JP
Citation: Y. Merrouche et al., HIGH DOSE-INTENSITY OF IRINOTECAN ADMINISTERED EVERY 3 WEEKS IN ADVANCED CANCER-PATIENTS - A FEASIBILITY STUDY, Journal of clinical oncology, 15(3), 1997, pp. 1080-1086
PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY
Authors: ROUGIER P BUGAT R DOUILLARD JY CULINE S SUC E BRUNET P BECOUARN Y YCHOU M MARTY M EXTRA JM BONNETERRE J ADENIS A SEITZ JF GANEM G NAMER M CONROY T NEGRIER S MERROUCHE Y BURKI F MOUSSEAU M HERAIT P MAHJOUBI M
Citation: P. Rougier et al., PHASE-II STUDY OF IRINOTECAN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER IN CHEMOTHERAPY-NAIVE PATIENTS AND PATIENTS PRETREATED WITH FLUOROURACIL-BASED CHEMOTHERAPY, Journal of clinical oncology, 15(1), 1997, pp. 251-260
CORRELATION BETWEEN CLINICAL-RESPONSE TO INTERLEUKIN-2 AND HLA PHENOTYPES IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: BAIN C MERROUCHE Y PUISIEUX I BLAY JY NEGRIER S BONADONA V LASSET C LANIER F DUC A GEBUHRER L PHILIP T FAVROT MC
Citation: C. Bain et al., CORRELATION BETWEEN CLINICAL-RESPONSE TO INTERLEUKIN-2 AND HLA PHENOTYPES IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, British Journal of Cancer, 75(2), 1997, pp. 283-286
QUALITY OF FINAL CARE FOR TERMINAL CANCER-PATIENTS IN A COMPREHENSIVECANCER CENTER FROM THE POINT-OF-VIEW OF PATIENTS FAMILIES
Authors: MERROUCHE Y FREYER G SALTEL P REBATTU P
Citation: Y. Merrouche et al., QUALITY OF FINAL CARE FOR TERMINAL CANCER-PATIENTS IN A COMPREHENSIVECANCER CENTER FROM THE POINT-OF-VIEW OF PATIENTS FAMILIES, Supportive care in cancer, 4(3), 1996, pp. 163-168
PROGESTERONE DERIVATIVES IN CANCER CACHEX IA
Authors: FREYER G CATIMEL G MERROUCHE Y
Citation: G. Freyer et al., PROGESTERONE DERIVATIVES IN CANCER CACHEX IA, La Revue de medecine interne, 17(1), 1996, pp. 79-84
B7.1 GENE TRANSDUCTION OF HUMAN RENAL-CELL-CARCINOMA CELL-LINES RESTORES THE PROLIFERATIVE RESPONSE AND CYTOTOXIC FUNCTION OF ALLOGENEIC T-CELLS
Authors: BAIN C MERROUCHE Y PUISIEUX I DUC A COLOMBO MP FAVROT M
Citation: C. Bain et al., B7.1 GENE TRANSDUCTION OF HUMAN RENAL-CELL-CARCINOMA CELL-LINES RESTORES THE PROLIFERATIVE RESPONSE AND CYTOTOXIC FUNCTION OF ALLOGENEIC T-CELLS, International journal of cancer, 67(6), 1996, pp. 769-776
RESTRICTION OF THE T-CELL REPERTOIRE IN TUMOR-INFILTRATING LYMPHOCYTES FROM 9 PATIENTS WITH RENAL-CELL CARCINOMA - RELEVANCE OF THE CDR3 LENGTH ANALYSIS FOR THE IDENTIFICATION OF IN-SITU CLONAL T-CELL EXPANSIONS
Authors: PUISIEUX I BAIN C MERROUCHE Y MALACHER P KOURILSKY P EVEN J FAVROT M
Citation: I. Puisieux et al., RESTRICTION OF THE T-CELL REPERTOIRE IN TUMOR-INFILTRATING LYMPHOCYTES FROM 9 PATIENTS WITH RENAL-CELL CARCINOMA - RELEVANCE OF THE CDR3 LENGTH ANALYSIS FOR THE IDENTIFICATION OF IN-SITU CLONAL T-CELL EXPANSIONS, International journal of cancer, 66(2), 1996, pp. 201-208
INTENSIVE REGIMEN OF CYTOKINES WITH INTERLEUKIN-2 AND INTERFERON ALFA-2B IN SELECTED PATIENTS WITH METASTATIC RENAL-CARCINOMA
Authors: NEGRIER S MERCATELLO A BRET M MERROUCHE Y CORONEL B FAVROT M GASPARD M DOREZ D PHILIP I LANIER F THIESSE P OSKAM R PALMER P TABAH I MOSKOVTCHENKO JF PHILIP T
Citation: S. Negrier et al., INTENSIVE REGIMEN OF CYTOKINES WITH INTERLEUKIN-2 AND INTERFERON ALFA-2B IN SELECTED PATIENTS WITH METASTATIC RENAL-CARCINOMA, Journal of immunotherapy with emphasis on tumor immunology, 17(1), 1995, pp. 62-68
BRAIN METASTASES IN COLORECTAL-CANCER - AN UNUSUAL METASTATIC SITE - REPORT OF 15 CASES TREATED WITH RADIOTHERAPY
Authors: MARTEL I MORNEX F DESSEIGNE F CARRIE C RIVOIRE M KAEMMERLEN P LACROZE M REBATTU P MERROUCHE Y
Citation: I. Martel et al., BRAIN METASTASES IN COLORECTAL-CANCER - AN UNUSUAL METASTATIC SITE - REPORT OF 15 CASES TREATED WITH RADIOTHERAPY, European journal of cancer, 31A, 1995, pp. 741-741
A PHASE-II STUDY OF CPT-11 (IRINOTECAN) IN REFRACTORY TO 5FU COLORECTAL-CANCER WITH CURATIVE TREATMENT OF DELAYED DIARRHEA BY ACETORPHAN
Authors: MERROUCHE Y BUGAT R BRUNET R SEITZ JF CONROY T FABRE V NAMER M PIOLAT V MAHJOUBI M DROZ JP
Citation: Y. Merrouche et al., A PHASE-II STUDY OF CPT-11 (IRINOTECAN) IN REFRACTORY TO 5FU COLORECTAL-CANCER WITH CURATIVE TREATMENT OF DELAYED DIARRHEA BY ACETORPHAN, European journal of cancer, 31A, 1995, pp. 759-759
LENOGRASTIM PREVENTS MORBIDITY FROM INTENSIVE INDUCTION CHEMOTHERAPY IN THE TREATMENT OF INFLAMMATORY BREAST-CANCER
Authors: CHEVALLIER B CHOLLET P MERROUCHE Y ROCHE H FUMOLEAU P KERBRAT P GENOT Y FARGEOT P OLIVIER JP FIZAMES C CLAVEL M YVER A CHABERNAUD VC
Citation: B. Chevallier et al., LENOGRASTIM PREVENTS MORBIDITY FROM INTENSIVE INDUCTION CHEMOTHERAPY IN THE TREATMENT OF INFLAMMATORY BREAST-CANCER, Journal of clinical oncology, 13(7), 1995, pp. 1564-1571
PHASE-III RANDOMIZED STUDY OF 2 FLUOROURACIL COMBINATIONS WITH EITHERINTERFERON-ALFA-2A OR LEUCOVORIN FOR ADVANCED COLORECTAL-CANCER
Authors: DALLEY D LEVI J BELL D GREEN M SHERMAN P ZALCBERG J ZIMET A THOMSON D WALPOLE E ACKLAND S STEWART J SCHULLER J FOGL U WIRTH M LUTZ D SALOMON J VANTRAPPEN G VANCUTSEM E LEPOUTRE L DEFACQ L BURY J REGINSTER M FROIMTCHUK M DEOLIVEIRA MDLL SCALETZKY A KOCHA W SKILLINGS J WEINERMAN B SHORE T MAROUN J CRIPPS C GOEL R BATIST G BOOS G GADEBERG C KJAER M BRUNSGAARD N JAKOBSEN A MEJLHOLM J BERTELSEN K MADSEN EL JORGENSEN A SANDBERG E PYRHONEN S ISOKANGAS OP JOHANSSON R KATAJA V ROUGIER P BECOUARN Y BRUNET R FRANCOIS E NAMER M SEITZ J GIOVANNINI H REBATTU P MERROUCHE Y LANKISCH P HEISE J MAY B GREVING J SODOMANN C BERGERMANN H MERTELSMANN R SCHUPP M PORZSOLT F STEINACKER RM CARTEI G BAJETTA E COLLEONI M PANNUTI E FOSSER V BERG C RAVN H EGELI R GUILLOU P SOMERS S CAREY P PRIMROSE J SELBY P WARD U BUDDE M HOLDENER EE MAN A MASSIMINI G SMITH H LUYKX R BLAES C YAP AKL HOLMSTROM S COCKEY L
Citation: D. Dalley et al., PHASE-III RANDOMIZED STUDY OF 2 FLUOROURACIL COMBINATIONS WITH EITHERINTERFERON-ALFA-2A OR LEUCOVORIN FOR ADVANCED COLORECTAL-CANCER, Journal of clinical oncology, 13(4), 1995, pp. 921-928
CLINICAL-APPLICATION OF RETROVIRAL GENE-TRANSFER IN ONCOLOGY - RESULTS OF A FRENCH STUDY WITH TUMOR-INFILTRATING LYMPHOCYTES TRANSDUCED WITH THE GENE OF RESISTANCE TO NEOMYCIN
Authors: MERROUCHE Y NEGRIER S BAIN C COMBARET V MERCATELLO A CORONEL B MOSKOVTCHENKO JF TOLSTOSHEV P MOEN R PHILIP T FAVROT MC
Citation: Y. Merrouche et al., CLINICAL-APPLICATION OF RETROVIRAL GENE-TRANSFER IN ONCOLOGY - RESULTS OF A FRENCH STUDY WITH TUMOR-INFILTRATING LYMPHOCYTES TRANSDUCED WITH THE GENE OF RESISTANCE TO NEOMYCIN, Journal of clinical oncology, 13(2), 1995, pp. 410-418
PHASE-I STUDY OF RP 49532A, A NEW PROTEIN-SYNTHESIS INHIBITOR, IN PATIENTS WITH ADVANCED REFRACTORY SOLID TUMORS
Authors: CATIMEL G COQUARD R GUASTALLA JP MERROUCHE Y LEBAIL N ALAKL MK DUMORTIER A FOY M CLAVEL M
Citation: G. Catimel et al., PHASE-I STUDY OF RP 49532A, A NEW PROTEIN-SYNTHESIS INHIBITOR, IN PATIENTS WITH ADVANCED REFRACTORY SOLID TUMORS, Cancer chemotherapy and pharmacology, 35(3), 1995, pp. 246-248
MUCOEPIDERMOID LUNG-TUMORS - 2 NEW CASES AND A REVIEW OF THE LITERATURE
Authors: VOOG E MERROUCHE Y BAILLY C REBATTU P
Citation: E. Voog et al., MUCOEPIDERMOID LUNG-TUMORS - 2 NEW CASES AND A REVIEW OF THE LITERATURE, Bulletin du cancer, 82(3), 1995, pp. 208-210
CLINICAL-APPLICATION OF GENE-TRANSFER IN ONCOLOGY
Authors: FAVROT M PHILIP T MERROUCHE Y
Citation: M. Favrot et al., CLINICAL-APPLICATION OF GENE-TRANSFER IN ONCOLOGY, Bulletin du cancer, 82(3), 1995, pp. 234-235
TREATMENT OF INTERLEUKIN-2-INDUCED THROMBOCYTOPENIA BY INTRAVENOUS IMMUNOGLOBULIN
Authors: COTTIN V NEGRIER S RANCHERE JY MERCATELLO A MERROUCHE Y NEGRIER C PHILIP T
Citation: V. Cottin et al., TREATMENT OF INTERLEUKIN-2-INDUCED THROMBOCYTOPENIA BY INTRAVENOUS IMMUNOGLOBULIN, European journal of cancer, 30A(14), 1994, pp. 2187-2187
A PHASE-I ANTIEMETIC STUDY OF MDL-73,147EF, A NOVEL 5-HYDROXYTRYPTAMINE ANTAGONIST IN CANCER-PATIENTS RECEIVING EMETOGENIC CHEMOTHERAPY
Authors: MERROUCHE Y CATIMEL G REBATTU P DUMORTIER A GUASTALLA JP OGRADY P CLAVEL M
Citation: Y. Merrouche et al., A PHASE-I ANTIEMETIC STUDY OF MDL-73,147EF, A NOVEL 5-HYDROXYTRYPTAMINE ANTAGONIST IN CANCER-PATIENTS RECEIVING EMETOGENIC CHEMOTHERAPY, Annals of oncology, 5(6), 1994, pp. 549-551
SUBCUTANEOUS LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND ALPHA-INTERFERON IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA
Authors: RAVAUD A NEGRIER S CANY L MERROUCHE Y LEGUILLOU M BLAY JY CLAVEL M GASTON R OSKAM R PHILIP T
Citation: A. Ravaud et al., SUBCUTANEOUS LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND ALPHA-INTERFERON IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, British Journal of Cancer, 69(6), 1994, pp. 1111-1114
Risultati: 1-25 | 26-30